公开(公告)号：US09732162B2

公开(公告)日：2017-08-15

申请号：US13831862

申请日：2013-03-15

Applicant: SANOFI

Inventor： Ercole Rao ,  Vincent Mikol ,  Danxi Li ,  Jochen Kruip ,  Matthew Davison

IPC: C07K16/24 ,  A61K39/00 ,  C07K16/46 ,  A61K47/48

CPC classification number: C07K16/468 ,  C07K16/244 ,  C07K16/247 ,  C07K2317/31 ,  C07K2317/64 ,  C07K2317/76

Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

公开(公告)号：US20170218090A1

公开(公告)日：2017-08-03

申请号：US15463806

申请日：2017-03-20

Applicant: Ablexis, LLC

Inventor： Larry Green ,  Hiroaki Shizuya

IPC: C07K16/46 ,  A01K67/027

CPC classification number: C07K16/461 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/18 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/64 ,  C12N15/8509 ,  C12N2510/02

Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.

公开(公告)号：US20170210825A1

公开(公告)日：2017-07-27

申请号：US15466587

申请日：2017-03-22

Applicant: BAYER INTELLECTUAL PROPERTY GMBH

Inventor： Bing LIU ,  David LIGHT ,  Zhuozhi WANG ,  Douglas SCHNEIDER

IPC: C07K16/46 ,  A61K45/06 ,  A61K39/395 ,  C07K16/36 ,  C07K16/30

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6809 ,  A61K47/6821 ,  A61K47/6827 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6869 ,  A61K2039/505 ,  C07K16/3069 ,  C07K16/3076 ,  C07K16/36 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/64 ,  Y02A50/412

Abstract: This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.

公开(公告)号：US20170183420A1

公开(公告)日：2017-06-29

申请号：US15453603

申请日：2017-03-08

Applicant: Sangamo Therapeutics, Inc.

Inventor： Philip D. Gregory ,  Michael C. Holmes

IPC: C07K16/32 ,  C07K16/28

CPC classification number: C07K16/32 ,  A61K35/17 ,  A61K35/26 ,  C07K16/2863 ,  C07K2317/622 ,  C07K2317/64 ,  Y02A50/463

Abstract: Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.

公开(公告)号：US20170181414A1

公开(公告)日：2017-06-29

申请号：US15408114

申请日：2017-01-17

Applicant: Ablexis, LLC

Inventor： Larry Green ,  Hiroaki Shizuya

IPC: A01K67/027 ,  C07K16/46

CPC classification number: C07K16/461 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/18 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/64 ,  C12N15/8509 ,  C12N2510/02

Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.

公开(公告)号：US20170174786A1

公开(公告)日：2017-06-22

申请号：US15281493

申请日：2016-09-30

Applicant: Hoffmann-La Roche Inc.

Inventor： Marina Bacac ,  Christian Klein ,  Wolfgang Schaefer ,  Stefan Klostermann ,  Sabine Imhof-Jung ,  Michael Molhoj ,  Joerg Thomas Regula ,  Pablo Umana ,  Sylvia Herter ,  Christiane Neumann

IPC: C07K16/40 ,  C07K16/30 ,  C07K16/46 ,  C07K16/28

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/3007 ,  C07K16/3053 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/66 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

公开(公告)号：US09683044B2

公开(公告)日：2017-06-20

申请号：US13971584

申请日：2013-08-20

Applicant: Gliknik Inc.

Inventor： David Block ,  Henrik Olsen

IPC: C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  C07K16/24 ,  C07K16/32 ,  C07K1/00 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/241 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/30 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/732 ,  Y02A50/412

Abstract: The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.

公开(公告)号：US20170158749A1

公开(公告)日：2017-06-08

申请号：US15305996

申请日：2015-04-23

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Laurence J.N. COOPER ,  Hillary Gibbons CARUSO ,  Simon OLIVARES ,  Sonny ANG

IPC: C07K14/725 ,  A61K39/395 ,  C07K14/715 ,  C07K14/705 ,  C07K16/28

CPC classification number: C07K14/7051 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70521 ,  C07K14/7153 ,  C07K16/2809 ,  C07K16/2863 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/70 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/515

Abstract: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting cells that express elevated levels of antigen (e.g., cancer cells) with CAR T-cell therapies are provided.

公开(公告)号：US09663574B2

公开(公告)日：2017-05-30

申请号：US15160364

申请日：2016-05-20

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Bruce A. Andrien, Jr. ,  Douglas L. Sheridan ,  Paul P. Tamburini ,  Yi Wang

IPC: A61K39/395 ,  C07K16/36 ,  C07K16/00 ,  C07K16/28 ,  C07K16/18 ,  C07K16/40 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/28 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.

公开(公告)号：US09650446B2

公开(公告)日：2017-05-16

申请号：US14205248

申请日：2014-03-11

Applicant: Xencor, Inc.

Inventor： Gregory Moore ,  Matthew Bernett ,  Rumana Rashid ,  John Desjarlais

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28

CPC classification number: C07K16/468 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/528 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/94

Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.